Medicxi Ventures Management (Jersey) Ltd

In its 13F for Q3 2024 (holdings as of September 30, 2024, filed October 15, 2024), Medicxi Ventures Management (Jersey) Ltd reported 4 stock positions worth $528.9 million. Its top holding was Centessa Pharmaceuticals (CNTA) at 60.4% of the portfolio, followed by Phathom Pharmaceuticals (PHAT, 25.5%) and Newamsterdam Pharma (NAMS, 9.0%). Its holdings were unchanged from Q2 2024.

Most Recent 13F
Q2 2026
Location
ST. HELIER, Y9
CIK
0001715579
Portfolio Value
$528.9M (Q3 2024)
SEC Filing
0000950123-24-009687 ↗ filed Oct 15, 2024

Holdings Value

0$200.0M$400.0M$600.0M$800.0M$1.0B Q1 2024: $449.2M Q1 2024 Q2 2024: $335.3M Q2 2024 Q3 2024: $528.9M $528.9M Q3 2024 Q4 2024: $529.0M Q4 2024 Q1 2025: $437.7M Q1 2025 Q2 2025: $427.3M Q2 2025 Q3 2025: $744.4M Q3 2025 Q4 2025: $835.0M Q4 2025 Q1 2026: $981.8M Q1 2026 Q2 2026: $177.4M Q2 2026

Holdings 4 stocks · $528.9M
CNTA Centessa Pharmaceuticals Ltd. 60.35% 19,963,157 $319.2M No change
PHAT Phathom Pharmaceuticals Inc. 25.52% 7,464,572 $135.0M No change
NAMS Newamsterdam Pharma Co. NV 9.01% 2,869,565 $47.6M No change
AURA Aura Biosciences Inc. 5.12% 3,039,892 $27.1M No change

Portfolio Sells Q2 2024 → Q3 2024
None this quarter.

Portfolio Buys Q2 2024 → Q3 2024
None this quarter.

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 3$177.4MPHAT, NAMS, AURA
Q1 2026 4$981.8MCNTA, NAMS, PHAT, AURA
Q4 2025 5$835.0MCNTA, PHAT, NAMS, RAPT THERAPEUTICS INC, AURA
Q3 2025 5$744.4MCNTA, PHAT, NAMS, RAPT THERAPEUTICS INC, AURA
Q2 2025 5$427.3MCNTA, PHAT, NAMS, RAPT, AURA
Q1 2025 5$437.7MCNTA, NAMS, PHAT, RAPT THERAPEUTICS INC, AURA
Q4 2024 5$529.0MCNTA, NAMS, PHAT, RAPT THERAPEUTICS INC, AURA
Q3 2024 4$528.9MCNTA, PHAT, NAMS, AURA
Q2 2024 4$335.3MCNTA, PHAT, NAMS, AURA
Q1 2024 5$449.2MCNTA, PHAT, NAMS, MRUS, AURA